← All trials
NCT06060301
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2023
- Primary completion
- Nov 1, 2023
- Completion date
- Nov 20, 2023
- First posted
- Sep 29, 2023
- Last posted
- Sep 29, 2023
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cairo UniversityLead sponsor
- Cairo UniversityReponsible party - principal investigator
- Cairo UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.